<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>merkezi önemde. * **Üç &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/merkezi-onemde-uc/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Jan 2026 20:19:13 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>merkezi önemde. * **Üç &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>SPARK Trial: New Treatment for Triple-Negative Breast Cancer</title>
		<link>https://bioengineer.org/spark-trial-new-treatment-for-triple-negative-breast-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 20:18:47 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[ana konu. 2. **TNBC combination therapy**: Tedavi edilen spesifik kanser türü (Üçlü]]></category>
		<category><![CDATA[İçeriğe göre en uygun 5 etiket: **SPARK Trial]]></category>
		<category><![CDATA[immunotherapy clinical trial** Açıklama: 1. **SPARK Trial**: Çalışmanın doğrudan adı]]></category>
		<category><![CDATA[İşte verilen içeriğe uygun 5 etiket: **SPARK Trial]]></category>
		<category><![CDATA[Kanser İmmünoterapisi** * **SPARK Trial:** Çalışmanın doğrudan adı]]></category>
		<category><![CDATA[merkezi önemde. * **Üç]]></category>
		<category><![CDATA[metastatic breast cancer treatment]]></category>
		<category><![CDATA[Metastatik Meme Kanseri Tedavisi]]></category>
		<category><![CDATA[Sitravatinib Tislelizumab]]></category>
		<category><![CDATA[Sitravatinib-Tislelizumab Kombinasyonu]]></category>
		<category><![CDATA[TNBC combination therapy]]></category>
		<category><![CDATA[Üçlü Negatif Meme Kanseri]]></category>
		<guid isPermaLink="false">https://bioengineer.org/spark-trial-new-treatment-for-triple-negative-breast-cancer/</guid>

					<description><![CDATA[In the evolving landscape of cancer treatment, a pivotal study uncovers promising results involving the combination of Sitravatinib and Tislelizumab for patients grappling with locally recurrent or metastatic triple-negative breast cancer (TNBC). Conducted as part of the SPARK Trial, this multi-cohort, single-arm phase II clinical trial has gained attention for its innovative approach. The study, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320450</post-id>	</item>
	</channel>
</rss>
